View All Immutep News. Immutep - Annual report to shareholders. 22 Oct 2024 01:10 PM. On behalf of the Board, I’m pleased to present Immutep Limiteds ...
Oct 2024 - Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha (efti).
Oct 2024 - A snapshot of the stocks on the move, featuring Nanoveu (ASX:NVU), MoneyMe (ASX:MME) and Alicanto Minerals (ASX:AQI).